Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Acquisitions & Divestments (2016 - 2018)

Ironwood Pharmaceuticals' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $19.9 million for Q4 2018.

  • For Q4 2018, Change in Acquisitions & Divestments fell 28.48% year-over-year to $19.9 million; the TTM value through Dec 2018 reached $99.2 million, down 71.41%, while the annual FY2018 figure was $99.2 million, 71.41% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2018 was $19.9 million at Ironwood Pharmaceuticals, up from $16.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $133.8 million in Q1 2017 and bottomed at $13.9 million in Q2 2018.
  • The 5-year median for Change in Acquisitions & Divestments is $50.6 million (2014), against an average of $58.1 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 460.71% in 2014 before it plummeted 88.15% in 2018.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $52.5 million in 2014, then grew by 23.26% to $64.7 million in 2015, then plummeted by 48.31% to $33.4 million in 2016, then dropped by 16.99% to $27.8 million in 2017, then fell by 28.48% to $19.9 million in 2018.
  • Per Business Quant, the three most recent readings for IRWD's Change in Acquisitions & Divestments are $19.9 million (Q4 2018), $16.8 million (Q3 2018), and $13.9 million (Q2 2018).